Abstract
CD25, CD27, CD30 and CD40 are receptors for IL-2, CD70, CD153 and CD154, respectively, which provide important signaling for both B- and T-cell immune responses. We therefore examined the sera of patients with Waldenstrom’s macroglobulinemia (WM), a B-cell disorder characterized by excess IgM secreting bone marrow lymphoplasmacytic cells (LPC) for the presence of soluble CD25, CD27, CD30, CD40, IL-2, CD153, and CD154. Sera were from patients with active disease and off-therapy. Sera from healthy age matched donors (HD) was used for controls. The results of these studies were as follows:
. | . | WM ELISA Results . | HD ELISA Results . | ||||
---|---|---|---|---|---|---|---|
. | p-value . | n= . | median . | range . | n= . | median . | range . |
sCD25 pg/ml | 2.647x10−6 | 41 | 3418.99 | 3–19756.2 | 20 | 573.6 | 184.96–891.03 |
IL-2 pg/ml | 0.72385 | 41 | 22.96 | 3–76.83 | 20 | 11.07 | 5.64–64.7 |
sCD27 U/ml | 2.4727x10−7 | 26 | 7.45 | 0–19.42 | 10 | 0 | 0–2.78 |
sCD70 | ND | ND | ND | ND | ND | ND | ND |
sCD30 U/ml | 0.00088 | 25 | 89.25 | 0–550.81 | 15 | 39.12 | 0–135.25 |
sCD153 ng/ml | 0.68388 | 25 | 8.18 | 0–43.8 | 15 | 5.65 | 0–24.82 |
sCD40 pg/ml | 0.02484 | 25 | 101.39 | 11.76–584.99 | 11 | 50.73 | 0–150.5 |
sCD154 pg/ml | 0.81317 | 55 | 949.58 | 92–4973.16 | 17 | 1078.03 | 351.88–2323.38 |
. | . | WM ELISA Results . | HD ELISA Results . | ||||
---|---|---|---|---|---|---|---|
. | p-value . | n= . | median . | range . | n= . | median . | range . |
sCD25 pg/ml | 2.647x10−6 | 41 | 3418.99 | 3–19756.2 | 20 | 573.6 | 184.96–891.03 |
IL-2 pg/ml | 0.72385 | 41 | 22.96 | 3–76.83 | 20 | 11.07 | 5.64–64.7 |
sCD27 U/ml | 2.4727x10−7 | 26 | 7.45 | 0–19.42 | 10 | 0 | 0–2.78 |
sCD70 | ND | ND | ND | ND | ND | ND | ND |
sCD30 U/ml | 0.00088 | 25 | 89.25 | 0–550.81 | 15 | 39.12 | 0–135.25 |
sCD153 ng/ml | 0.68388 | 25 | 8.18 | 0–43.8 | 15 | 5.65 | 0–24.82 |
sCD40 pg/ml | 0.02484 | 25 | 101.39 | 11.76–584.99 | 11 | 50.73 | 0–150.5 |
sCD154 pg/ml | 0.81317 | 55 | 949.58 | 92–4973.16 | 17 | 1078.03 | 351.88–2323.38 |
Considering our recent studies demonstrating a role for mast cells (MC) in supporting WM cell growth (JCO 2004 22:571S), we examined bone marrow LPC along with MC from WM patients for expression of CD25, CD27 and CD40 and/or their ligands by flow cytometry and RT-PCR analysis. The results of these studies are as follows:
. | Flow Cytometry . | RT-PCR . | ||
---|---|---|---|---|
. | WM . | MC . | WM . | MC . |
CD25 | 4/10 (40%) | 2/7 (29%) | 7/9 (78%) | 7/15 (47%) |
IL-2 | ND | ND | ND | ND |
CD27 | 5/12 (42%) | 2/8 (25%) | 7/7 (100%) | 4/7 (57%) |
CD70 | 6/6 (100%) | 10/11 (91%) | 7/7 (100%) | 2/7 (29%) |
CD30 | 1/21 (4.7%) | ND | ND | ND |
CD153 | 3/7 (43%) | 12/13 (92%) | 2/2 (100%) | 9/11 (82%) |
CD40 | 25/30 (83%) | ND | ND | ND |
CD154 | 2/3 (67%) | 9/13 (69%) | 7/9 (78%) | ND |
. | Flow Cytometry . | RT-PCR . | ||
---|---|---|---|---|
. | WM . | MC . | WM . | MC . |
CD25 | 4/10 (40%) | 2/7 (29%) | 7/9 (78%) | 7/15 (47%) |
IL-2 | ND | ND | ND | ND |
CD27 | 5/12 (42%) | 2/8 (25%) | 7/7 (100%) | 4/7 (57%) |
CD70 | 6/6 (100%) | 10/11 (91%) | 7/7 (100%) | 2/7 (29%) |
CD30 | 1/21 (4.7%) | ND | ND | ND |
CD153 | 3/7 (43%) | 12/13 (92%) | 2/2 (100%) | 9/11 (82%) |
CD40 | 25/30 (83%) | ND | ND | ND |
CD154 | 2/3 (67%) | 9/13 (69%) | 7/9 (78%) | ND |
The above studies demonstrate high levels of circulating immunoregulatory receptors, and expression of these receptors and/or their ligands on WM tumor and mast cells. Studies addressing their role in immune dysregulation in WM are underway.
Author notes
Corresponding author